Exhibit 99.1

   TRANSGENOMIC, INC. ANNOUNCES RESIGNATION OF DIRECTOR AND APPOINTS NEW BOARD
                                     MEMBER

    OMAHA, Neb., March 5 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC
Bulletin Board: TBIO) announced that it has accepted Roland J Santoni's
resignation as a member of the Board of Directors, including his position as
Chairman of the Compensation Committee and member of the Audit Committee of the
Company, effective March 1, 2007. Mr. Santoni has been a member of the Board of
Directors since March 2000. Regarding Mr. Santoni's departure from the Board,
Craig Tuttle, the Company's President and CEO, stated, "We appreciate and
respect the long-term dedication that Mr. Santoni has brought to the company."

    The Board of Directors has appointed Rodney S. Markin, M.D., Ph.D. to the
Board to fill the vacancy created by Mr. Santoni's resignation. Dr. Markin is
currently Professor of Pathology and Microbiology and Surgery, Senior Associate
Dean for Clinical Affairs, College of Medicine at the University of Nebraska
Medical Center and Chairman, President and CEO of UNMC Physicians (the UNMC
Medical Practice). Dr. Markin's professional and academic research interests
have focused on clinical laboratory automation, which include, but are not
limited to, robotics, information systems, medical utilization management and
outcomes optimization, microbiological detection systems and he was a leader in
bringing liver transplantation expertise to UNMC. Dr. Markin also founded
LAB-InterLink, a spin-out of the University of Nebraska Medical Center. This
start-up provided hardware and software solutions for clinical laboratory
automation.

    In making this announcement, Craig Tuttle stated, "We are very excited to
have Dr. Markin join the Company's Board of Directors. Dr. Markin has a
tremendous reputation as both a practicing Pathologist and as a successful
entrepreneur. He brings a detailed understanding of clinical medicine and
oncology diagnosis to the Board. He will provide significant leadership to the
Company as we expand our own genetic CLIA laboratory offering and our expanding
activities in the cancer discovery area." Mr. Tuttle further noted, "We are
entering an exciting time at Transgenomic where we are applying our many years
of mutation discovery and technical expertise to expand our product and service
offerings and drive the company's growth. Adding Dr. Markin to the Board will
aid us significantly in achieving these goals."

    About Transgenomic:  A decade of discovery 1997 - 2007

    Transgenomic is a global biotechnology company that provides unique
systems, products, discovery and laboratory testing services to the academic and
medical research, clinical and pharmaceutical markets for automated high
sensitivity genetic variation and mutation analysis in the fields of
pharmacogenomics and personalized medicine. This is accomplished through their
offerings of WAVE(R) DHPLC Systems, reagents, consumables and assay kits,
automated cytogenetics systems and Transgenomic Discovery and CLIA Lab Services.
To date there have been over 1,200 WAVE systems installed in over 600 customer
sites in over 35 countries and approximately 1,500 publications utilizing
Transgenomic products or services. Transgenomic Discovery and Lab Services
utilize their technology and expertise to provide a menu of mutation scanning
tests for over 700 cancer-associated genes and more than 60 validated diagnostic
tests to meet the needs of pharmaceutical and biotech companies, research and
clinical laboratories, physicians and patients. For more information about the
innovative systems, products and services offered by Transgenomic, please visit:
www.transgenomic.com.



    Transgenomic Cautionary Statements

    Certain statements in this press release constitute "forward-looking
statements" of Transgenomic within the meaning of the Private Securities
Litigation Reform Act of 1995, which involve known and unknown risks,
uncertainties and other factors that may cause our actual results to be
materially different from any future results, performance or achievements
expressed or implied by such statements. Forward-looking statements include, but
are not limited to, those with respect to management's current views and
estimates of future economic circumstances, industry conditions, company
performance and financial results, including the ability of the Company to grow
its involvement in the diagnostic products and services markets. The known
risks, uncertainties and other factors affecting these forward-looking
statements are described from time to time in Transgenomic's reports to the
Securities and Exchange Commission. Any change in such factors, risks and
uncertainties may cause the actual results, events and performance to differ
materially from those referred to in such statements. Accordingly, the company
claims the protection of the safe harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995 with respect
to all statements contained in this press release. All information in this press
release is as of the date of the release and Transgenomic does not undertake any
duty to update this information, including any forward-looking statements,
unless required by law.

SOURCE  Transgenomic, Inc.
    -0-                             03/05/2007
    /CONTACT:  Debra Schneider, Chief Financial Officer of Transgenomic, Inc.,
+1-402-452-5400, or fax, +1-402-452-5461, investorrelations@transgenomic.com/
    /Web site:  http://www.transgenomic.com /
    (TBIO)